S 3427

Neuroscience Center of Excellence Act of 2021

Congress: 117 (2021–2023, Ended)
Chamber: Senate
Policy Area: Health
Introduced: Dec 16, 2021
Current Status: Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Sponsor introdu
Latest Action: Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Sponsor introductory remarks on measure: CR S9263-9264) (Dec 16, 2021)
Official Text: https://www.congress.gov/bill/117th-congress/senate-bill/3427

Sponsor

Name: Sen. Collins, Susan M. [R-ME]
Party: Republican • **State:** ME • **Chamber:** Senate

Cosponsors (1 total)

Cosponsor	Party / State	Role	Date Joined
Sen. Lujan, Ben Ray [D-NM]	D · NM		Dec 16, 2021

Committee Activity

Committee	Chamber	Activity	Date
Health, Education, Labor, and Pensions Committee	Senate	Referred To	Dec 16, 2021

Subjects & Policy Tags

Policy Area:

Health

Related Bills

No related bills are listed.

Summary (as of Dec 16, 2021)

Neuroscience Center of Excellence Act of 2021

This bill requires the Food and Drug Administration (FDA) to establish the Neuroscience Center of Excellence to address neuroscience diseases and disorders (e.g., addiction, Alzheimer's disease, and psychotic disorders).

The center must carry out various activities, including (1) coordinating with FDA programs that focus on certain areas, such as drug evaluation; (2) convening periodic public meetings to engage with stakeholders to address challenges associated with developing medical products for neuroscience diseases and disorders; (3) establishing a program to facilitate the collection and systemic use of patient experience data to develop such medical products; and (4) convening a public meeting to discuss how to promote equity and the inclusion of traditionally underrepresented populations in the development of such medical products.

The FDA must take actions related to these issues, such as issuing final guidance with recommendations on the collection and use of patient experience data for developing such medical products.

The Government Accountability Office must report to Congress a study that (1) reviews the participation of traditionally underrepresented populations in clinical trials for such medical products, and (2) provides recommendations for improving the participation of these populations.

Actions Timeline

- **Dec 16, 2021:** Introduced in Senate
- **Dec 16, 2021:** Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Sponsor introductory remarks on measure: CR S9263-9264)